2021
Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses
Cui C, Wang J, Fagerberg E, Chen PM, Connolly KA, Damo M, Cheung JF, Mao T, Askari AS, Chen S, Fitzgerald B, Foster GG, Eisenbarth SC, Zhao H, Craft J, Joshi NS. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell 2021, 184: 6101-6118.e13. PMID: 34852236, PMCID: PMC8671355, DOI: 10.1016/j.cell.2021.11.007.Peer-Reviewed Original ResearchConceptsCD8 TB cellsTfh cellsLung adenocarcinomaTfh-B cell interactionsTumor-specific B cellsFollicular helper cellsAnti-tumor immunityB cell signaturesCell effector functionsGerminal center formationGC B cellsCD4 THelper cellsTumor controlTumor neoantigensEffector functionsCell collaborationCell responsesCell signatureTumor cellsSignature correlatesNeoantigensCell functionCD4
2019
Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment
Mills B, Connolly K, Ye J, Murphy J, Uccello T, Han B, Zhao T, Drage M, Murthy A, Qiu H, Patel A, Figueroa N, Johnston C, Prieto P, Egilmez N, Belt B, Lord E, Linehan D, Gerber S. Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment. Cell Reports 2019, 29: 406-421.e5. PMID: 31597100, PMCID: PMC6919969, DOI: 10.1016/j.celrep.2019.08.095.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyMultiple preclinical mouse modelsPancreatic ductal adenocarcinoma patientsEffective neoadjuvant therapyAdvanced metastatic diseaseStereotactic body radiationDuctal adenocarcinoma patientsLate-stage diseaseInterferon-gamma productionBody radiation therapySystemic tumor immunityPreclinical mouse modelsNeoadjuvant approachNeoadjuvant therapyLiver metastasesMetastatic diseaseCD8 TTumor immunityAdenocarcinoma patientsImmune microenvironmentTumor reductionMS administrationTherapy resultsPancreatic tumorsGamma production
2016
Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes
Connolly K, Belt B, Figueroa N, Murthy A, Patel A, Kim M, Lord E, Linehan D, Gerber S. Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes. Oncotarget 2016, 5: 86522-86535. PMID: 27852031, PMCID: PMC5349932, DOI: 10.18632/oncotarget.13287.Peer-Reviewed Original ResearchConceptsEfficacy of radiotherapyImmune responseSyngeneic tumor cell linesCancer typesIntratumoral immune infiltrateAnti-tumor immunityIntratumoral immune responseEffect of radiotherapyMechanism of radiotherapyEffectiveness of radiotherapyChemokine axesRadioresponsive tumorsLocal radiotherapyImmunosuppressive cellsImmune infiltratesRT failureTumor recurrenceImmune cellsCCR5 antagonistsMurine modelHigh incidenceRadiotherapyTumor growthRT efficacyTumor site
2013
Radio‐responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors
Gerber S, Lim J, Connolly K, Sedlacek A, Barlow M, Murphy S, Egilmez N, Lord E. Radio‐responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors. International Journal Of Cancer 2013, 134: 2383-2392. PMID: 24154990, PMCID: PMC3949198, DOI: 10.1002/ijc.28558.Peer-Reviewed Original ResearchConceptsRadiation therapyIL-12Immune cellsImmune responseEffectiveness of RTEfficacy of RTCD8 T cellsIntratumoral immune cellsCytokines IL-12Effectiveness of therapyOutcome of radiotherapyEfficacy of treatmentComplete remissionResponsive tumorsCure rateNonresponsive tumorsT cellsImmune activityAntitumor effectsImmune systemCombinatorial treatmentTumor modelColon adenocarcinomaNonrespondersTumors